OBJECTIVES: The study assessed the appropriateness of coronary revascularization in Ontario, Canada, and examined its association with longer-term outcomes. BACKGROUND: Although appropriate use criteria for coronary revascularization have been developed to improve the rational use of cardiac invasive procedures, it is unknown whether greater adherence to appropriateness guidelines is associated with improved clinical outcomes in stable coronary artery disease. METHODS:A population-based cohort of stable patients undergoing cardiac catheterization was assembled from April 1, 2006, to March 31, 2007. The appropriateness for coronary revascularization at the time of coronary angiography was retrospectively adjudicated using the appropriate use criteria. Clinical outcomes between coronary revascularization and medical treatment without revascularization, stratified by appropriateness categories, were compared. RESULTS: In 1,625 patients with stable coronary artery disease, percutaneous coronary intervention or coronary artery bypass grafting was only performed in 69% who had an appropriate indication for coronary revascularization. Coronary revascularization was associated with a lower adjusted hazard of death or acute coronary syndrome (hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.42 to 0.88) at 3 years compared with medical therapy in appropriate patients. The rate of coronary revascularization was 54% in the uncertain category and 45% in the inappropriate category. No significant difference in death or acute coronary syndrome between coronary revascularization and no revascularization in the uncertain category (HR: 0.57; 95% CI: 0.28 to 1.16) and the inappropriate category (HR: 0.99; 95% CI: 0.48 to 2.02) was observed. CONCLUSIONS: Using the appropriateness use criteria, we identified substantial underutilization and overutilization of coronary revascularization in contemporary clinical practice. Underutilization of coronary revascularization is associated with significantly increased risks of adverse outcomes in patients with appropriate indications.
RCT Entities:
OBJECTIVES: The study assessed the appropriateness of coronary revascularization in Ontario, Canada, and examined its association with longer-term outcomes. BACKGROUND: Although appropriate use criteria for coronary revascularization have been developed to improve the rational use of cardiac invasive procedures, it is unknown whether greater adherence to appropriateness guidelines is associated with improved clinical outcomes in stable coronary artery disease. METHODS: A population-based cohort of stable patients undergoing cardiac catheterization was assembled from April 1, 2006, to March 31, 2007. The appropriateness for coronary revascularization at the time of coronary angiography was retrospectively adjudicated using the appropriate use criteria. Clinical outcomes between coronary revascularization and medical treatment without revascularization, stratified by appropriateness categories, were compared. RESULTS: In 1,625 patients with stable coronary artery disease, percutaneous coronary intervention or coronary artery bypass grafting was only performed in 69% who had an appropriate indication for coronary revascularization. Coronary revascularization was associated with a lower adjusted hazard of death or acute coronary syndrome (hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.42 to 0.88) at 3 years compared with medical therapy in appropriate patients. The rate of coronary revascularization was 54% in the uncertain category and 45% in the inappropriate category. No significant difference in death or acute coronary syndrome between coronary revascularization and no revascularization in the uncertain category (HR: 0.57; 95% CI: 0.28 to 1.16) and the inappropriate category (HR: 0.99; 95% CI: 0.48 to 2.02) was observed. CONCLUSIONS: Using the appropriateness use criteria, we identified substantial underutilization and overutilization of coronary revascularization in contemporary clinical practice. Underutilization of coronary revascularization is associated with significantly increased risks of adverse outcomes in patients with appropriate indications.
Authors: Daniel M Alyesh; Milan Seth; David C Miller; James M Dupree; John Syrjamaki; Devraj Sukul; Simon Dixon; Eve A Kerr; Hitinder S Gurm; Brahmajee K Nallamothu Journal: Circ Cardiovasc Qual Outcomes Date: 2018-06
Authors: Jaskaran S Kang; Maria C Bennell; Feng Qiu; Merril L Knudtson; Peter C Austin; Dennis T Ko; Harindra C Wijeysundera Journal: CMAJ Open Date: 2016-08-08
Authors: Paul S Chan; Sunil V Rao; Deepak L Bhatt; John S Rumsfeld; Hitinder S Gurm; Brahmajee K Nallamothu; Matthew A Cavender; Kevin F Kennedy; John A Spertus Journal: J Am Coll Cardiol Date: 2013-09-18 Impact factor: 24.094
Authors: Manesh R Patel; John H Calhoon; Gregory J Dehmer; James Aaron Grantham; Thomas M Maddox; David J Maron; Peter K Smith Journal: J Nucl Cardiol Date: 2017-10 Impact factor: 5.952
Authors: Mohammed Qintar; John A Spertus; Kensey L Gosch; John Beltrame; Faraz Kureshi; Ali Shafiq; Tracie Breeding; Karen P Alexander; Suzanne V Arnold Journal: Eur Heart J Qual Care Clin Outcomes Date: 2016-03-25
Authors: Michael P Thomas; Craig S Parzynski; Jeptha P Curtis; Milan Seth; Brahmajee K Nallamothu; Paul S Chan; John A Spertus; Manesh R Patel; Steven M Bradley; Hitinder S Gurm Journal: PLoS One Date: 2015-09-17 Impact factor: 3.240
Authors: Andrew Czarnecki; Treesa J Prasad; Julie Wang; Harindra C Wijeysundera; Asim N Cheema; Vladimír Dz̆avík; Madhu K Natarajan; Chris S Simpson; Derek Y So; Jaffer Syed; Jack V Tu; Dennis T Ko Journal: Open Heart Date: 2015-02-14
Authors: Harmony R Reynolds; Leslee J Shaw; James K Min; John A Spertus; Bernard R Chaitman; Daniel S Berman; Michael H Picard; Raymond Y Kwong; C Noel Bairey-Merz; Derek D Cyr; Renato D Lopes; Jose Luis Lopez-Sendon; Claes Held; Hanna Szwed; Roxy Senior; Gilbert Gosselin; Rajesh Gopalan Nair; Ahmed Elghamaz; Olga Bockeria; Jiyan Chen; Alexander M Chernyavskiy; Balram Bhargava; Jonathan D Newman; Sasa B Hinic; Joanna Jaroch; Angela Hoye; Jeffrey Berger; William E Boden; Sean M O'Brien; David J Maron; Judith S Hochman Journal: JAMA Cardiol Date: 2020-07-01 Impact factor: 14.676